SCHEMBL8660951

SCHEMBL8660951

COc1ccc(C(OCCOCCOCCOCCOCCOCCOC(=O)CCC(=O)O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A11 P48066 4/20 0.45
SLC6A1 P30531 2/20 0.45
MAPT P10636 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TP53 P04637 3/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC6A12 P48065 1/20 0.40
SLC6A13 Q9NSD5 1/20 0.40
PDE4B Q07343 1/20 0.40
KIF11 P52732 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575117 1.00 SLC6A11 (0.45) SLC6A11SLC6A1MAPTALDH1A1TP53
SCHEMBL14866488 0.96 SLC6A11 (0.47) SLC6A11SLC6A1MAPTALDH1A1TP53
SCHEMBL31003057 0.91 SLC6A11 (0.45) SLC6A11SLC6A1MAPTALDH1A1TP53
SCHEMBL26176914 0.90 TDP1 (0.46) SLC6A1KIF11NPC1
SCHEMBL26176892 0.90 TDP1 (0.46) SLC6A1KIF11NPC1
SCHEMBL26176895 0.90 TDP1 (0.46) SLC6A1KIF11NPC1
SCHEMBL335718 0.89 SLC6A11 (0.46) SLC6A11SLC6A1MAPTALDH1A1TP53
SCHEMBL16472613 0.88 SLC6A11 (0.47) SLC6A11SLC6A1MAPTALDH1A1TP53
SCHEMBL15318305 0.85 SLC6A11 (0.45) SLC6A11SLC6A1MAPTTP53LMNA
SCHEMBL5598775 0.85 SLC6A11 (0.48) SLC6A11SLC6A1MAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5807837-A ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL SANKYO COMPANY, LIMITED (JP) 1998-09-15 US disclosed
US-5674856-A TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS SANKYO COMPANY, LIMITED (JP) 1997-10-07 US disclosed
EP-0611075-B1 Modified oligodeoxyribonucleotides, their preparation and their therapeutic use SANKYO CO (JP) 1996-12-18 EP disclosed
EP-0611075-A1 Modified oligodeoxyribonucleotides, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1994-08-17 EP disclosed